Institute of Immunology and Immunotherapy NIHR Birmingham Biomedical Research Centre, University Hospitals NHS Foundation Trust and University of Birmingham, Birmingham, UK.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
J Crohns Colitis. 2022 May 11;16(Supplement_2):ii64-ii72. doi: 10.1093/ecco-jcc/jjab185.
Interleukin 23 [IL-23] plays a key role in the pathogenesis of both Crohn's disease [CD] and ulcerative colitis [UC], promoting a Th17 cell-related immune response. The combined blockade of IL-23 and IL-12 with ustekinumab has been demonstrated to be safe and effective in the treatment of inflammatory bowel disease [IBD]. Studies on preclinical models and observations of other immune-mediated diseases, such as psoriasis, suggest that the selective inhibition of IL-23 could be beneficial in IBD. Four monoclonal antibodies [risankizumab, mirikizumab, brazikumab and guselkumab] are currently in advance clinical trials for either CD or UC. In this review, we provide an overview of the main results from published studies of selective anti IL-23 agents.
白细胞介素 23（IL-23）在克罗恩病（CD）和溃疡性结肠炎（UC）的发病机制中起着关键作用，促进 Th17 细胞相关免疫反应。乌司奴单抗联合阻断 IL-23 和 IL-12 已被证明在治疗炎症性肠病（IBD）方面是安全有效的。在临床前模型研究和其他免疫介导性疾病（如银屑病）的观察中表明，选择性抑制 IL-23 可能对 IBD 有益。目前有四种单克隆抗体（risankizumab、mirikizumab、brazikumab 和 guselkumab）正在针对 CD 或 UC 进行临床试验。在这篇综述中，我们概述了已发表的选择性抗 IL-23 药物研究的主要结果。
Zotero 插件